国药现代：原料药阿戈美拉汀上市申请获批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of the active pharmaceutical ingredient Agomelatine, which is primarily used for treating adult depression [1] Group 1: Company Information - The company involved is Guoyao Modern (国药现代), with its wholly-owned subsidiary Jiangsu Weichida Pharmaceutical Co., Ltd. (国药江苏威奇达) receiving the approval [1] - Agomelatine acts on melatonin receptors MT1 and MT2 and antagonizes 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] Group 2: Product Information - The clinical application of Agomelatine is mainly for the treatment of adult depression [1]